Serum IL-5 and IL-13 consistently serve as the best predictors for the blood eosinophilia phenotype in adult asthmatics

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 71, Issue 8, 2016, Pages 1192-1202

  Agache, I ^a   Strasser, D S ^b   Klenk, A ^b   Agache, C ^c,d   Farine, H ^b   Ciobanu, C ^c   Groenen, P M A ^b   Akdis, C A ^d,e  

^a TRANSILVANIA UNIVERSITY OF BRASOV   (Romania)

^b ACTELION PHARMACEUTICALS LTD   (Switzerland)

^c Theramed Medical Center   (Romania)

^d CHRISTINE KÜHNE CENTER FOR ALLERGY RESEARCH AND EDUCATION CK CARE   (Switzerland)

^e UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

biomarkers; eosinophilic asthma; IL 13; IL 5; phenotype

Indexed keywords

CORTICOSTEROID; EOSINOPHIL PROTEIN X; EOTAXIN; EOTAXIN 3; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN E; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 16; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONOCYTE CHEMOTACTIC PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; TRANSCRIPTION FACTOR RUNX2; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; BIOLOGICAL MARKER;

ADULT; ARTICLE; ASPIRIN EXACERBATED RESPIRATORY DISEASE; ASTHMA; BLOOD CELL COUNT; DISEASE CLASSIFICATION; DISEASE CONTROL; DISEASE SEVERITY; EOSINOPHIL COUNT; EOSINOPHILIA; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MONOTHERAPY; ONSET AGE; PHENOTYPE; PREDICTIVE VALUE; PRICK TEST; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RESPIRATORY TRACT ALLERGY; SKIN TEST; SMOKING; SPUTUM; BLOOD; CLUSTER ANALYSIS; EOSINOPHIL; LEUKOCYTE COUNT; LUNG FUNCTION TEST; METABOLOMICS; MIDDLE AGED; PROCEDURES; PROGNOSIS;

ADULT; ASTHMA; BIOMARKERS; CLUSTER ANALYSIS; EOSINOPHILIA; EOSINOPHILS; FEMALE; HUMANS; INTERLEUKIN-13; INTERLEUKIN-5; LEUKOCYTE COUNT; MALE; METABOLOMICS; MIDDLE AGED; PHENOTYPE; PROGNOSIS; RESPIRATORY FUNCTION TESTS; SKIN TESTS;

EID: 84967184848     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12906     Document Type: Article

References (55)

1. Fajt ML, Wenzel SE. Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care. J Allergy Clin Immunol 2015;135:299–310.
2. Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 2009;180:388–395.
3. Agache I, Akdis C, Jutel M, Virchow JC. Untangling asthma phenotypes and endotypes. Allergy 2012;67:835–846.
4. Raedler D, Ballenberger N, Klucker E, Böck A, Otto R, Prazeres da Costa O et al. Identification of novel immune phenotypes for allergic and non-allergic childhood asthma. J Allergy Clin Immunol 2015;135:81–91.
5. Lotvall J, Akdis CA, Bacharier LB, Bjermer L, Casale TB, Custovic A et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol 2011;127:355–360.
6. Agache IO. From phenotypes to endotypes to asthma treatment. Curr Opin Allergy Clin Immunol 2013;13:249–256.
7. Agache IO. Endotype driven treatment of asthma. Curr Treat Options Allergy 2014;1:198–212.
8. Woodruff PG, Boushey HA, Dolganov GM, Barker CS, Yang YH, Donnelly S et al. Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. Proc Natl Acad Sci USA 2007;104:15858–15863.
9. Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011;365:1088–1098.
10. Agache I, Kazunari S, Morita H, Akdis M, Akdis CA. The complex type 2 endotype in allergy and asthma: from laboratory to bedside. Curr Allergy Asthma Rep 2015;15:29.
11. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89–95.
12. Szefler SJ, Wenzel S, Brown R, Erzurum SC, Fahy JV, Hamilton RG et al. Asthma outcomes: biomarkers. J Allergy Clin Immunol 2012;129(Suppl. 3):S9–S23.
13. Clemmer GL, Wu AC, Rosner B, McGeachie MJ, Litonjua AA, Tantisira KG et al. Measuring the corticosteroid responsiveness endophenotype in asthmatic patients. J Allergy Clin Immunol 2015;136:274–281.
14. Malinovschi A, Fonseca JA, Jacinto T, Alving K, Janson C. Exhaled nitric oxide levels and blood eosinophil counts independently associate with wheeze and asthma events in National Health and Nutrition Examination Survey subjects. J Allergy Clin Immunol 2013;132:821–827.
15. Hastie AT, Moore WC, Li H, Rector BM, Ortega VE, Pascual RM et al. Biomarker surrogates do not accurately predict sputum eosinophil and neutrophil percentages in asthmatic subjects. J Allergy Clin Immunol 2013;132:72–80.
16. Lemière C, Ernst P, Olivenstein R, Yamauchi Y, Govindaraju K, Ludwig MS et al. Airway inflammation assessed by invasive and non-invasive means in severe asthma: eosinophilic and noneosinophilic phenotypes. J Allergy Clin Immunol 2006;118:1033–1039.
17. Tran TN, Khatry DB, Ke X et al. High blood eosinophil count is associated with more frequent asthma attacks in asthma patients. Ann Allergy Asthma Immunol 2014;113:19–24.
18. Newby C, Agbetile J, Hargadon B, Monteiro W, Green R, Pavord I et al. Lung function decline and variable airway inflammatory pattern: longitudinal analysis of severe asthma. J Allergy Clin Immunol 2014;134:287–294.
19. Khatry DB, Gossage DL, Geba GP, Parker JM, Jarjour NN, Busse WW et al. Discriminating sputum-eosinophilic asthma: accuracy of cutoffs in blood eosinophil measurements versus a composite index, ELEN. J Allergy Clin Immunol 2015;136:812–814.
20. Fowler SJ, Tavernier G, Niven R. High blood eosinophil counts predict sputum eosinophilia in patients with severe asthma. J Allergy Clin Immunol 2015;135:822–824.
21. Stern G, de Jongste J, van der Valk R et al. Fluctuation phenotyping based on daily fraction of exhaled nitric oxide values in asthmatic children. J Allergy Clin Immunol 2011;128:293–300.
22. Silkoff PE, Lent AM, Busacker AA, Katial RK, Balzar S, Strand M et al. Exhaled nitric oxide identifies the persistent eosinophilic phenotype in severe refractory asthma. J Allergy Clin Immunol 2005;116:1249–1255.
23. Pavord ID et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012;380:651–659.
24. Ortega H, Li H, Suruki R, Albers F, Gordon D, Yancey S. Cluster analysis and characterization of response to mepolizumab. A step closer to personalized medicine for patients with severe asthma. Ann Am Thorac Soc 2014;11:1011–1017.
25. Jia G, Erickson RW, Choy DF, Mosesova S, Wu LC, Solberg OD et al. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol 2012;130:647–654.
26. Kanemitsu Y, Matsumoto H, Izuhara K, Tohda Y, Kita H, Horiguchi T et al. Increased periostin associates with greater airflow limitation in patients receiving inhaled corticosteroids. J Allergy Clin Immunol 2013;132:305–312.
27. Reddel HK, Taylor DR, Bateman ED et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009;180:59–99.
28. Heinzerling LM, Burbach GJ, Edenharter G, Bachert C, Bindslev-Jensen C, Bonini S et al. GA(2)LEN skin test study I: GA(2)LEN harmonization of skin prick testing: novel sensitization patterns for inhalant allergens in Europe. Allergy 2009;64:1498–1506.
29. Fokkens W, Lund V, Mullol J. European Position Paper on Rhinosinusitis and Nasal Polyps Group European position paper on rhinosinusitis and nasal polyps 2007. Rhinology 2007;45(Suppl. 20):1–139.
30. Kowalski ML, Asero R, Bavbek S, Blanca M, Blanca-Lopez N, Bochenek G et al. Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs. Allergy 2013;68:1219–1232.
31. Ayres JG, Miles JF, Barnes PJ. Brittle asthma. Thorax 1998;53:315–321.
32. American Thoracic Society/European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med 2005;171:912–930.
33. Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med 2011;184:602–615.
34. Miller MR et al. Standardisation of spirometry. Eur Respir J 2005;26:319–338.
35. Quanjer PH, Stanojevic S, Cole TJ et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J 2012;40:1324–1343.
36. Djukanović R, Sterk PJ, Fahy JV, Hargreave FE. Standardised methodology of sputum induction and processing. Eur Respir J Suppl 2002;37:1s–2s.
37. Efthimiadis A, Spanevello A, Hamid Q et al. Methods of sputum processing for cell counts, immunohistochemistry and in situ hybridisation. Eur Respir J 2002;20(Suppl. 37):19s–23s.
38. Strasser D et al. Development of a decision-making biomarker for CRTH2 antagonism in clinical studies. New Horizons Transl Med 2015;4:118–125.
39. Troyanskaya O et al. Missing value estimation methods for DNA microarrays. Bioinformatics 2001;6:520–525.
40. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 1979;6:65–70.
41. Spector SL, Tan RA. Is a single blood eosinophil count a reliable marker for “eosinophilic asthma? J Asthma 2012;49:807–810.
42. Katz LE, Gleich GJ, Hartley BF, Yancey SW, Ortega HG. Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma. Ann Am Thorac Soc 2014;11:531–536.
43. Hoffmann JN, Yu K, Bagni RK, Lan Q, Rothman N, Purdue MP. Intra-individual variability over time in serum cytokine levels among participants in the prostate, lung, colorectal, and ovarian cancer screening Trial. Cytokine 2011;56:145–148.
44. Wagener AH, de Nijs SB, Lutter R, Sousa AR, Weersink EJ, Bel EH et al. External validation of blood eosinophils, FE(NO) and serum periostin as surrogates for sputum eosinophils in asthma. Thorax 2015;70:115–120.
45. Matsusaka M, Kabata H, Fukunaga K, Suzuki Y, Masaki K, Mochimaru T et al. Phenotype of asthma related with high serum periostin levels. Allergol Int 2015;64:175–180.
46. Castro M, Wenzel SE, Bleecker ER, Pizzichini E, Kuna P, Busse WW et al. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med 2014;2:879–890.
47. Kim CK, Callaway Z, Kim DW, Kita H. Eosinophil degranulation is more important than eosinophilia in identifying asthma in chronic cough. J Asthma 2011;48:994–1000.
48. Sedgwick JB, Vrtis RF, Jansen KJ, Kita H, Bartemes K, Busse WW. Peripheral blood eosinophils from patients with allergic asthma contain increased intracellular eosinophil-derived neurotoxin. J Allergy Clin Immunol 2004;114:568–574.
49. De Boever EH, Ashman C, Cahn AP, Locantore NW, Overend P, Pouliquen IJ et al. Efficacy and safety of an anti-IL-13 mAb in patients with severe asthma: a randomized trial. J Allergy Clin Immunol 2014;133:989–996.
50. Barlow JL, Bellosi A, Hardman CS, Drynan LF, Wong SH, Cruickshank JP et al. Innate IL-13-producing nuocytes arise during allergic lung inflammation and contribute to airways hyperreactivity. J Allergy Clin Immunol 2012;129:191–198.
51. Christianson CA, Goplen NP, Zafar I, Irvin C, Good JT Jr, Rollins DR et al. Persistence of asthma requires multiple feedback circuits involving type 2 innate lymphoid cells and IL-33. J Allergy Clin Immunol 2015;136:59–68.
52. Albano GD, Zhao J, Etling EB, Park SY, Hu H, Trudeau JB et al. IL-13 desensitizes β2-adrenergic receptors in human airway epithelial cells through a 15-lipoxygenase/G protein receptor kinase 2 mechanism. J Allergy Clin Immunol 2015;135:1144–1153.
53. Kraft M, Hamid Q, Chrousos GP, Martin RJ, Leung DY. Decreased steroid responsiveness at night in nocturnal asthma. Is the macrophage responsible? Am J Respir Crit Care Med 2001;163:1219–1225.
54. Saglani S et al. Interleukin-33 promotes airway remodelling in paediatric severe steroid resistant asthma. J Allergy Clin Immunol 2013;132:676–685.
55. Harb H, Raedler D, Ballenberger N, Böck A, Kesper DA, Renz H et al. Childhood allergic asthma is associated with increased IL-13 and FOXP3 histone acetylation. J Allergy Clin Immunol 2015;136:200–202.